Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Rhea-AI Summary

Adaptimmune Therapeutics (NASDAQ: ADAP), a pioneer in solid tumor cancer cell therapy treatments, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York, NY. The company's CEO, Adrian Rawcliffe, will engage in a fireside chat on February 6, 2025, at 3:00 p.m. EST.

The event will be accessible via webcast, and interested parties can join through the provided link or through the 'Events' section under the 'News Center' tab in the 'Investors & Media' area of Adaptimmune's website. A replay of the presentation will be available after the event.

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.

• Guggenheim Securities SMID Cap Biotech Conference, New York, NY
  • Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. EST
  • Webcast link: https://wsw.com/webcast/guggen2/adap/1969770

This event can also be accessed by visiting 'Events', under the 'News Center' tab, in the 'Investors & Media' section of Adaptimmune's website at www.adaptimmune.com. Following the event, a replay of the presentation will be made available.

About Adaptimmune
Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
Juli.Miller@adaptimmune.com

Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239017

FAQ

When is Adaptimmune's (ADAP) presentation at the Guggenheim Securities SMID Cap Biotech Conference 2025?

Adaptimmune's CEO will present at the conference on February 6, 2025, at 3:00 p.m. EST.

How can investors watch Adaptimmune's (ADAP) Guggenheim Securities conference presentation?

Investors can watch the presentation through the webcast link provided or by visiting the 'Events' section under the 'News Center' tab in the 'Investors & Media' area of Adaptimmune's website.

Will there be a replay available of Adaptimmune's (ADAP) Guggenheim Securities conference presentation?

Yes, a replay of the presentation will be made available after the event on Adaptimmune's website.

What type of event will Adaptimmune (ADAP) participate in at the Guggenheim Securities conference?

Adaptimmune's CEO Adrian Rawcliffe will participate in a fireside chat at the conference.